Buprenorphine Detoxification - BBDVI - 19
Sponsor
National Institute on Drug Abuse (NIDA) (NIH)
Overall Status
Completed
CT.gov ID
NCT00000237
Collaborator
University of Vermont (Other)
0
1
Study Details
Study Description
Brief Summary
The purpose of this study is to examine the long-term efficacy of alternate-day dosing schedules in promoting treatment compliance in the absence of confounding behavioral contingencies.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 2 |
Study Design
Study Type:
Interventional
Primary Purpose:
Treatment
Official Title:
Buprenorphine Detoxification - BBDVI
Study Start Date
:
May 1, 1997
Outcome Measures
Primary Outcome Measures
- Drug use []
- Retention []
- Weeks abstinent []
- Weeks continuous abstinence []
- Overall treatment outcome []
- Opioid dependence and psychiatric status []
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Please contact site for information.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Treatment Research Center | Burlington | Vermont | United States | 05401 |
Sponsors and Collaborators
- National Institute on Drug Abuse (NIDA)
- University of Vermont
Investigators
- Principal Investigator: Warren Bickel, Ph.D., University of Vermont
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
,
,
ClinicalTrials.gov Identifier:
NCT00000237
Other Study ID Numbers:
- NIDA-06969-19
- R01-06969-19
First Posted:
Sep 21, 1999
Last Update Posted:
Aug 17, 2005
Last Verified:
May 1, 1997